Morgan Stanley Downgrades Bristol-Myers Squibb Co. (BMY) to Equalweight
Get Alerts BMY Hot Sheet
Price: $44.70 -8.51%
Rating Summary:
6 Buy, 26 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
6 Buy, 26 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Morgan Stanley analyst David Risinger downgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Overweight to Equalweight with a price target of $62.00 (from $70.00).
For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.
Shares of Bristol-Myers Squibb Co. closed at $62.89 yesterday.
You May Also Be Interested In
- Bristol-Myers Squibb Co. (BMY) PT Lowered to $64 at Truist Securities
- Teradyne (TER) PT Raised to $125 at TD Cowen
- Bristol-Myers Squibb (BMY) stock slips despite earnings beat
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!